Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial

NCT04310943 is registered in ClinicalTrials.gov with Zhou Chengzhi as lead sponsor.

NCT NCT04310943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04310943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial
Lead sponsor
Zhou Chengzhi
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
December 1, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma stage iv